Novel Microplate Design Improves Assay Performance
Porvair Sciences has developed the Krystal 2000 microplate range to address performance limiting well-to-well crosstalk inherent in most assay plates.
Incorporating unique individual clear cups molded into either a black or white polypropylene matrix, crosstalk is eliminated and the sensitivity, photometric accuracy and repeatability of your bottom reading absorbance, fluorescence and luminescence measurements markedly improved.
Maintaining industry standard 96-well microplate dimensions the Krystal 2000 range is fully compatible with all commercially available plate readers, robotic sample processors and automated liquid handling systems.
Constructed in ultra-pure grade polystyrene, Krystal 2000 microplates are available in opaque white, solid black and black and white combination formats. For sensitive fluorescence measurements the black plate provides the all-absorbing background needed to minimise background interference. The opaque white plate maximizes reflectivity enabling even weakly emitting luminescence assays to be routinely undertaken.
In addition to optimized luminescence and fluorescence measurements the unique design offers improved cell binding efficiency and allows the convenience of direct measurements on bottom reading spectrophotometers and inverted microscopes.
To download a technical report that evaluates well-to-well crosstalk in commercially available microplates used for luminescence measurements please visit www.porvair-sciences.com/
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...